Protara Therapeutics to Present at Investment Conference
Protara Therapeutics, Inc. (Nasdaq: TARA), a forward-thinking company committed to creating innovative therapies for cancer and rare diseases, has announced some exciting news. The management team will be presenting at the prestigious H.C. Wainwright 26th Annual Global Investment Conference, highlighting their dedication to healthcare innovation.
Details of the Event
This important conference will take place in New York, where Protara's team will provide insights and updates on their clinical-stage developments. Their presentation is scheduled for Monday, September 9, 2024, at 1:30 PM ET. This event serves as a valuable opportunity for Protara to highlight their progress and connect with potential investors.
How to Access the Presentation
While the presentation will be conducted live, it will also be available for online viewing. Those interested can visit the Events and Presentations section on the Protara Therapeutics website to access the live webcast. Additionally, a recording will be accessible for a limited time after the live event for anyone unable to attend.
About Protara Therapeutics
Protara is leading the way in biotechnology, concentrating on therapies aimed at enhancing the lives of patients facing difficult health challenges. Their main candidate, TARA-002, is a cell-based therapy currently in clinical trials targeting non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations. Notably, Protara is conducting a Phase 2 trial for NMIBC patients who have not responded to or have not been treated with Bacillus Calmette-Guérin (BCG).
Advancing Innovative Treatments
Beyond TARA-002, Protara is also progressing with IV Choline Chloride, an essential phospholipid substrate that acts as a nutritional alternative for patients needing parenteral nutrition. This innovative therapy plays a crucial role for patients who are unable to meet their choline requirements through conventional dietary means.
Contact Information for Protara Therapeutics
For more information about Protara Therapeutics and their ongoing initiatives, Justine O'Malley is available for inquiries. You can reach her at 646-817-2836 or via email at Justine.OMalley@protaratx.com.
Frequently Asked Questions
What is Protara Therapeutics focused on?
Protara Therapeutics is dedicated to developing transformative therapies for cancer and rare diseases.
When is Protara's presentation at the H.C. Wainwright conference?
The presentation is scheduled for September 9, 2024, at 1:30 PM ET.
How can I access Protara's presentation?
You can access the presentation via a live webcast on the Protara Therapeutics website, with an archived version available afterward.
What is TARA-002?
TARA-002 is Protara’s investigational cell-based therapy designed to treat non-muscle invasive bladder cancer and lymphatic malformations.
Who can I contact for more information about Protara Therapeutics?
For any inquiries, you can contact Justine O'Malley at Justine.OMalley@protaratx.com or call 646-817-2836.